Core Viewpoint - Meili Tianyuan Medical Health (02373) anticipates significant revenue and profit growth for 2025, driven by both external expansion and strong internal growth [1] Group 1: Financial Projections - The company expects to achieve revenue of no less than RMB 3 billion in 2025, representing a year-on-year growth of no less than 16% [1] - Adjusted net profit is projected to be no less than RMB 380 million, with a year-on-year increase of no less than 40% [1] - Net profit is expected to reach no less than RMB 340 million, reflecting a year-on-year growth of no less than 34% [1] Group 2: Growth Drivers - The board attributes the performance improvement primarily to accelerated external expansion, including the acquisition of the second-ranked brand in China's beauty industry, Nairui'er, which enhances market share and boosts revenue and profit [1] - Strong internal growth is driven by increased brand momentum and a growing customer base, contributing to internal revenue growth [1] - The rising proportion of high-margin medical business revenue, combined with the release of operational efficiency, further drives profit margin growth [1]
美丽田园医疗健康涨近5% 预期2025年经调整净利润同比增长不少于40%